title: [Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation].
abstract: Following surgical resection locally advanced oesophageal carcinomas exhibit a bad prognosis and therefore neoadjuvant therapeutic strategies were developed. Because success of therapy is associated with the extent of tumor regression in this context, the introduction of objective histopathological criteria seems to be very important. This study included 67 patients with oesophageal carcinomas (cT2-cT4 cNx cM0) that were treated with a cisplatin- and 5-fluorouracil-containing simultaneous radiochemotherapy. In 43 patients squamous cell, in 24 cases adenocarcinomas were diagnosed. After completion of therapy, a surgical resection and a histopathological examination of the tissue specimens were performed. The extent of tumor regression was histologically evaluated and therapy-induced alterations were graded semiquantitatively. Thereby, a significantly favorable prognosis was observed in the group of patients that showed a regression of carcinomas of 90% or more. Additionally, the extent of a resorptive-histiocytic reaction, giant cells and lymphocytic infiltrates correlated with the grade of regression. These results underline the importance of an exact examination and histomorphological evaluation of the response for the assessment of survival probability after neoadjuvant radiochemotherapy of oesophageal carcinomas.
authors.affiliation: Institut für Pathologie, Universität zu Köln, Joseph-Stelzmann-Strasse 9, 50931 Köln. s-e.baldus@uni-koeln.de
authors.forename: S E
authors.initials: SE
authors.lastname: Baldus
authors.forename: S P
authors.initials: SP
authors.lastname: Mönig
authors.forename: W
authors.initials: W
authors.lastname: Schröder
authors.forename: R
authors.initials: R
authors.lastname: Metzger
authors.forename: S
authors.initials: S
authors.lastname: Lang
authors.forename: T K
authors.initials: TK
authors.lastname: Zirbes
authors.forename: J
authors.initials: J
authors.lastname: Thiele
authors.forename: R P
authors.initials: RP
authors.lastname: Müller
authors.forename: H P
authors.initials: HP
authors.lastname: Dienes
authors.forename: A H
authors.initials: AH
authors.lastname: Hölscher
authors.forename: P M
authors.initials: PM
authors.lastname: Schneider
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy / Q000601:surgery*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D016896:Treatment Outcome